Publicação
Economic burden of Parkinson’s disease : a multinational, real-world, cost-of-illness study
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Chaudhuri, K. Ray | |
| dc.contributor.author | Azulay, Jean-Philippe | |
| dc.contributor.author | Odin, Per | |
| dc.contributor.author | Lindvall, Susanna | |
| dc.contributor.author | Domingos, Josefa | |
| dc.contributor.author | Alobaidi, Ali | |
| dc.contributor.author | Kandukuri, Prasanna L. | |
| dc.contributor.author | Chaudhari, Vivek S. | |
| dc.contributor.author | Parra, Juan Carlos | |
| dc.contributor.author | Yamazaki, Toru | |
| dc.contributor.author | Oddsdottir, Julia | |
| dc.contributor.author | Wright, Jack | |
| dc.contributor.author | Martinez-Martin, Pablo | |
| dc.date.accessioned | 2026-03-25T12:38:58Z | |
| dc.date.available | 2026-03-25T12:38:58Z | |
| dc.date.issued | 2024-03 | |
| dc.description.abstract | Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson’s Disease Specific Program™, conducted in the USA, five European countries, and Japan. Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson’s disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. Conclusions: People with Parkinson’s disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson’s disease and their caregivers, whilst also substantially impacting societal costs. | eng |
| dc.identifier.citation | Chaudhuri, K.R., Azulay, JP., Odin, P. et al. Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study. Drugs - Real World Outcomes 11, 1–11 (2024). https://doi.org/10.1007/s40801-023-00410-1 | |
| dc.identifier.doi | 10.1007/s40801-023-00410-1 | |
| dc.identifier.issn | 2198-9788 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/62430 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Springer Nature | |
| dc.relation.hasversion | https://doi.org/10.1007/s40801-023-00410-1 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | economic burden | |
| dc.subject | Parkinson’s disease | |
| dc.title | Economic burden of Parkinson’s disease : a multinational, real-world, cost-of-illness study | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 11 | |
| oaire.citation.startPage | 1 | |
| oaire.citation.title | Drugs - Real World Outcomes | |
| oaire.citation.volume | 11 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |